Catalyst Pharmaceutical CPRX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $755.86M+6.6% | $709.17M+2.8% | $689.89M+5.7% | $652.8M+12.4% | $580.66M+12.2% | ||
| $130.83M+3.4% | $126.48M+18.9% | $106.41M+61.6% | $65.86M-7.6% | $71.27M+8.8% | ||
| $34.93M-6.0% | $37.17M+32.6% | $28.03M+50.3% | $18.65M-5.7% | $19.78M+1.2% | ||
| $18.77M-11.5% | $21.22M-24.6% | $28.12M+31.3% | $21.43M+52.8% | $14.02M-33.4% | ||
| $940.39M+5.2% | $894.03M+4.9% | $852.45M+12.4% | $758.74M+10.6% | $685.72M+10.0% | ||
| $994K-4.1% | $1.04M-3.7% | $1.08M-6.3% | $1.15M-7.3% | $1.24M-8.5% | ||
| $1.86M-4.0% | $1.94M-3.7% | $2.01M-3.6% | $2.08M-3.4% | $2.16M-3.2% | ||
| $121.97M-7.4% | $131.67M+2.4% | $128.64M-6.8% | $137.98M-6.3% | $147.33M-6.0% | ||
| $55.11M+4.4% | $52.77M+9.3% | $48.26M-4.8% | $50.7M+5.1% | $48.22M+4.9% | ||
| $27.29M+21.1% | $22.54M+17.6% | $19.17M-9.8% | $21.26M-12.2% | $24.21M+12.3% | ||
| $1.15B+4.0% | $1.1B+5.0% | $1.05B+8.2% | $971.92M+6.9% | $908.87M+6.7% | ||
| $7.15M-36.2% | $11.2M+23.2% | $9.1M+64.5% | $5.53M-50.6% | $11.2M-32.5% | ||
| $125.25M-7.9% | $135.95M+13.6% | $119.64M+11.3% | $107.48M+7.0% | $100.45M-3.5% | ||
| $446K+2.1% | $437K+2.1% | $428K+2.1% | $419K+2.2% | $410K+2.0% | ||
| $132.4M-10.0% | $147.15M+14.3% | $128.74M+13.9% | $113.01M+1.2% | $111.65M-7.5% | ||
| $2.24M-4.9% | $2.35M-4.5% | $2.46M-4.3% | $2.57M-4.1% | $2.68M-3.8% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $2.68M-3.8% | $2.79M-3.5% | $2.89M-3.4% | $2.99M-3.2% | $3.09M-3.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $280K+34.0% | $209K+29.8% | $161K-47.9% | $309K+19.3% | $259K-17.8% | ||
| $134.91M-9.9% | $149.71M+14.0% | $131.36M+13.3% | $115.89M+1.1% | $114.59M-7.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $122K-0.8% | $123K0.0% | $123K+0.8% | $122K0.0% | $122K+0.8% | ||
| $489.22M+1.9% | $479.96M+1.4% | $473.33M+2.5% | $461.87M+2.1% | $452.28M+2.3% | ||
| $523.35M+10.4% | $474.19M+6.1% | $446.79M+13.4% | $394.01M+15.2% | $341.9M+19.9% | ||
| $8K— | $0— | $0-100% | $31K+282% | -$17K-127% | ||
| $1.01B+6.1% | $954.27M+3.7% | $920.25M+7.5% | $856.03M+7.8% | $794.28M+9.2% | ||
| $1.15B+4.0% | $1.1B+5.0% | $1.05B+8.2% | $971.92M+6.9% | $908.87M+6.7% | ||
| $27.29M+21.1% | $22.54M+17.6% | $19.17M-9.8% | $21.26M-12.2% | $24.21M+12.3% | ||
| $27.29M+21.1% | $22.54M+17.6% | $19.17M-9.8% | $21.26M-12.2% | $24.21M+12.3% | ||
| $1.86M-4.0% | $1.94M-3.7% | $2.01M-3.6% | $2.08M-3.4% | $2.16M-3.2% | ||
| $55.11M+4.4% | $52.77M+9.3% | $48.26M-4.8% | $50.7M+5.1% | $48.22M+4.9% | ||
| $121.97M-7.4% | $131.67M+2.4% | $128.64M-6.8% | $137.98M-6.3% | $147.33M-6.0% | ||
| $1.86M-4.0% | $1.94M-3.7% | $2.01M-3.6% | $2.08M-3.4% | $2.16M-3.2% | ||
| $1.86M-4.0% | $1.94M-3.7% | $2.01M-3.6% | $2.08M-3.4% | $2.16M-3.2% | ||
| $125.25M-7.9% | $135.95M+13.6% | $119.64M+11.3% | $107.48M+7.0% | $100.45M-3.5% | ||
| $125.25M-7.9% | $135.95M+13.6% | $119.64M+11.3% | $107.48M+7.0% | $100.45M-3.5% | ||
| $2.68M-3.8% | $2.79M-3.5% | $2.89M-3.4% | $2.99M-3.2% | $3.09M-3.0% | ||
| $122K-0.8% | $123K0.0% | $123K+0.8% | $122K0.0% | $122K+0.8% | ||
| $0— | $0— | $0— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Catalyst Pharmaceutical cover its short-term obligations?
- Its current ratio is 7.10 — current assets exceed current liabilities.
- Where does Catalyst Pharmaceutical's balance sheet data come from?
- Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.